Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

DNSP-11 peptide icon, one bubble per amino acidDNSP-1111 residuesPPEAPAEDRSLEach bubble = one amino acid. Size = residue mass. Color = chemical class.

DNSP-11

CognitiveResearch
Unknown half-life·Injection/Nasal·4w on / 4w off

Also known as: DNSP-11, DNSP11

A single injection into the rat substantia nigra doubled resting dopamine levels for 28 days straight. DNSP-11 is an 11-amino-acid peptide carved from the proprotein region of GDNF, the brain's own dopamine neuron survival factor. It bypasses the GFRalpha1 receptor entirely, working through ERK1/2 signaling instead. No human has ever taken it in a clinical trial. Six published papers exist, all from one lab at the University of Kentucky. Researchers studying dopaminergic neuroprotection watch this compound closely, but anyone considering self-experimentation should understand the evidence base is thin and entirely preclinical.

What Is DNSP-11?

Doubled dopamine. Twenty-eight days from one injection. That result, from a direct intranigral injection in rats, put DNSP-11 on the map for neuroprotection researchers (Bradley et al. 2010)[1].

DNSP-11 (Dopamine Neuron Stimulating Peptide-11) is a synthetic 11-amino-acid peptide, sequence PPEAPAEDRSL-NH2, with a molecular weight of 1210.33 Da. It comes from the proprotein region of human glial cell line-derived neurotrophic factor (GDNF). Bradley's group at the University of Kentucky predicted that the GDNF prosequence could be cleaved at dibasic endopeptidase sites to yield smaller bioactive fragments. DNSP-11 was the standout.

The mechanism is what makes it interesting. Full-length GDNF needs the GFRalpha1/RET receptor complex and barely crosses the blood-brain barrier after peripheral dosing. DNSP-11 skips that receptor entirely. It activates ERK1/2 phosphorylation, blocks mitochondrial cytochrome c release, and keeps dopaminergic neurons alive through an independent survival pathway. In a standard 6-OHDA Parkinson's rat model, three weeks of intranasal dosing at 300 mcg reduced rotational behavior by roughly 50% (Stenslik et al. 2015)[2].

Intranasal delivery works. Tracer studies using 125I-labeled DNSP-11 confirmed the peptide reached the striatum and substantia nigra within 30 minutes of intranasal administration in rats. Rhesus macaques tolerated escalating intranasal doses up to 10 mg/day for 10 weeks without behavioral problems or weight loss (Stenslik et al. 2018)[3].

The honest assessment: six papers, one lab, zero human trials, no pharmaceutical company involvement. The preclinical signal is strong for a GDNF-pathway compound. The translation gap to humans remains completely uncharted.

How DNSP-11 Works

DNSP-11 comes from the proprotein domain of GDNF but acts nothing like its parent molecule. Full-length GDNF requires the GFRalpha1/RET receptor complex. DNSP-11 bypasses that system completely.

Instead, it activates ERK1/2 phosphorylation. ERK1/2 (extracellular signal-regulated kinase) is a key intracellular signaling cascade for neuronal survival, differentiation, and synaptic plasticity. Fuqua and colleagues confirmed this in vitro [4]. The downstream effect is prevention of mitochondrial cytochrome c release, which blocks the intrinsic apoptotic pathway in dopaminergic neurons.

What's unusual is the duration. A single intranigral injection in rats maintained raised dopamine and DOPAC levels for up to 28 days. That's far longer than you'd expect from an 11-amino-acid peptide with no formal pharmacokinetic half-life data. The working theory is that DNSP-11 triggers sustained intracellular signaling cascades or gene expression changes. The molecule itself clears quickly; the cellular program it activates does not.

In dopaminergic neurons specifically, DNSP-11 increases dopamine synthesis and turnover. Treated animals show raised DOPAC/dopamine ratios, meaning the neurons are producing and metabolizing more dopamine. This is distinct from reuptake inhibition or receptor agonism. The peptide is pushing the system to make more of its own neurotransmitter.

No anti-GDNF antibody formation has been observed with DNSP-11. That matters because immunogenicity has been a recurring problem in GDNF gene therapy trials.

DNSP-11 Benefits

  • DNSP-11 benefits center on dopaminergic neuroprotection, with all evidence coming from animal models at the University of Kentucky.
  • Doubled resting dopamine and DOPAC in the rat substantia nigra after a single intranigral injection, with effects persisting 28 days (Bradley et al. 2010)[1].
  • Cut apomorphine-induced rotational behavior by roughly 50% in the 6-OHDA Parkinson's rat model after three weeks of intranasal dosing at 300 mcg/day (Stenslik 2015)[2].
  • Promoted survival and neurite outgrowth of fetal mesencephalic neurons in culture and blocked staurosporine cytotoxicity in dopaminergic B65 cells (Bradley et al. 2010)[1].
  • Reached the striatum and substantia nigra within 30 minutes of intranasal delivery in rats; confirmed by 125I tracer imaging.
  • Tolerated at escalating intranasal doses up to 10 mg/day for 10 weeks in rhesus macaques, no adverse behavioral effects or weight loss (Stenslik 2018)[3]. That's roughly 33 times the proposed human dose without problems.

DNSP-11: Science vs Community Consensus

Science Only
Scientific Evidence
Weak
Based on 5 key studies·Research only

Preclinical evidence supports dopaminergic neuroprotection via ERK1/2 pathway; intranasal delivery confirmed in rat and NHP models.

Dosing studied: 100–300 mcg/day intranasal (rat optimal: 300 mcg; NHP escalation tolerated to 10 mg/day over 10 weeks)
Read the evidence (key study, limitations)

300 mcg/day intranasal increased nigrostriatal dopamine turnover and reduced 6-OHDA lesion effects in rats. Zero human trials initiated 2026.

Key Study

Stenslik et al. 2015 (PMID 25999268): repeated intranasal DNSP-11 in rat 6-OHDA Parkinson's model; 300 mcg produced greatest dopamine turnover increase and TH+ neuron sparing

Limitations

No human clinical trials. All data from rodents and rhesus macaques. No pharmacokinetic half-life has been published. The dose study tested 100, 300 and 1,000 mcg; 300 was optimal. Most recent publication is a 2022 conference abstract (Parmar, FASEB). No new papers 2023–2026.

Community Experience
Weak
3.5/5
Based on fewer than 10 Reddit mentions (r/peptides search 2026)

No meaningful community data.

Community dosing: No community protocol established
Read the reports

Fewer than 10 Reddit threads 2026. No established self-experimentation user base. No user-reported outcomes.

What users report (0)
    Common issues (0)
      Science-Only Evidence

      No human self-experimentation community exists to compare against scientific findings. All claimed benefits are extrapolated from preclinical animal models. Impossible to assess real-world alignment.

      DNSP-11 Dosage Guide

      SpeculativeVery limited human data: dose based on preclinical research
      LevelDose / InjectionFrequency
      Beginner100 mcg
      DailyTrack
      Moderate300 mcg
      DailyTrack
      Aggressive300 mcg
      DailyTrack
      Note:

      Reconstitution math first. A 10 mg vial with 2 mL bacteriostatic water gives you 5 mg/mL, or 5 mcg per microliter. For the 300 mcg target dose, you'll draw 60 microliters total (6 units on an insulin syringe) into a nasal atomizer device, split across both nostrils.

      With a 5 mg vial and 2 mL BAC water, concentration is 2.5 mg/mL. The 300 mcg dose becomes 120 microliters (12 units). That's a larger nasal volume; some users prefer the 10 mg vial for tighter delivery.

      The non-obvious thing: standard insulin syringe markings are too coarse for reliable 60 microliter accuracy. You'll want a precision nasal atomizer (MAD Nasal or equivalent) that can meter small volumes. A 10 microliter pipetting error at 300 mcg represents a 3.3% dose deviation.

      Don't confuse the 28-day effect duration with dosing frequency. That 28-day number came from a direct surgical injection into the substantia nigra, not intranasal delivery. Daily intranasal dosing is still the protocol.

      Verify C-terminal amidation (-NH2) on the CoA. The correct sequence is PPEAPAEDRSL-NH2 with MW 1210.33 Da. Non-amidated product has different biological activity.

      Cycling Protocol

      On Period
      4 weeks
      Off Period
      4 weeks

      No established human cycling protocols exist. The 4-on/4-off recommendation is precautionary given the complete absence of long-term human data. In rat studies, 3-week repeated intranasal dosing was used. In non-human primates, 10-week repeated dosing was tolerated. Discontinue immediately if any adverse effects occur.

      Calculate your DNSP-11 dose
      Free dosage calculator with syringe visualization

      Or use the universal Peptide Calculator for any peptide.

      DNSP-11 Protocols by Goal

      beginnerCommunity4 weeks on, 4 weeks off (precautionary: no established human cycling protocol)
      Induction
      Wk 1–4
      100 mcg · Daily · Intranasal

      Expected: Unknown in humans. In rat models: neurochemical changes at 100 mcg were observed but 300 mcg was the optimal dose. Any human benefit is entirely speculative.

      Monitor: No validated human monitoring protocol. Self-assess weekly for new neurological symptoms. Discontinue immediately if headache, dizziness, tremor, mood changes, or sleep disruption occur.

      How to Use DNSP-11

      1. 1
        Reconstitute the vial

        Add 2 mL bacteriostatic water to a 10 mg vial (yields 5 mg/mL, or 50 mcg per 10 microliters). For a 5 mg vial, same 2 mL BAC water gives 2.5 mg/mL.

      2. 2
        Step 2

        Draw the target dose into a precision nasal atomizer or insulin syringe. For 100 mcg beginner dose: 2 units from a 10 mg/2 mL vial, or 4 units from a 5 mg/2 mL vial. For 300 mcg moderate dose: 6 units from a 10 mg/2 mL vial, or 12 units from a 5 mg/2 mL vial.

      3. 3
        Step 3

        Transfer the drawn volume to a MAD Nasal atomizer device or equivalent precision nasal sprayer. Do not inject this intranasally using a syringe and needle.

      4. 4
        Tilt your head slightly forward (not backward)

        Deliver approximately half the volume into each nostril with a quick pump.

      5. 5
        Sniff gently after each actuation

        Do not inhale hard; you want olfactory and trigeminal pathway absorption, not lung delivery.

      6. 6
        Step 6

        Alternate which nostril receives the first spray each day.

      7. 7
        Dose in the morning

        Avoid dosing when significantly congested, as nasal congestion blocks olfactory absorption and reduces CNS delivery.

      8. 8
        Store reconstituted solution at 2 to 8 degrees Celsius

        Use within 4 weeks. Do not freeze-thaw repeatedly.

      Alternative Routes

      Intranasal

      100–300 mcg/day; consistent with all published animal studies

      Confirmed CNS penetration in rats: 125I-DNSP-11 detected in striatum and substantia nigra within 30 minutes of intranasal delivery. Total delivery volume ~50–150 µL split across both nostrils using a precision nasal atomizer. The olfactory and trigeminal nerve pathways provide direct CNS access.

      Subcutaneous

      No established SC dose. Rat intranigral injection used direct local delivery; NHP studies used intranasal only. No peripheral-to-CNS PK data.

      Peripheral SC injection of an 11-mer peptide would likely result in rapid proteolytic degradation with minimal CNS penetration across the intact BBB. Not supported by any published data for this compound.

      Intranigral injection (animal studies only)

      Single injection produced 28-day dopamine elevation in rats; no intranasal protocol has demonstrated equivalent duration

      Documented in animal literature long-duration effects via direct nigral ERK1/2 activation. Not a human route. Frequently misunderstood by readers infrequent dosing is sufficient for intranasal protocols.

      Mixing your own vial? Use the DNSP-11 reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

      DNSP-11 Stacking Protocols

      Works With

      Avoid

      Levodopa/Carbidopa

      DNSP-11 increases endogenous dopamine synthesis via ERK1/2 upregulation; combined with exogenous L-DOPA this could produce dopaminergic excess (agitation, dyskinesia, orthostatic hypotension).

      Do not combine
      Dopamine agonists (pramipexole, ropinirole)

      Additive dopaminergic effects entirely unstudied. Risk of dopaminergic excess syndrome in combination with DNSP-11-mediated dopamine upregulation.

      Do not combine
      MAO-B inhibitors (selegiline, rasagiline)

      Both MAO-B inhibitors and DNSP-11 increase dopamine availability through different mechanisms; combination could produce unpredictable dopaminergic excess.

      Antipsychotics (dopamine antagonists)

      Dopamine antagonists may counteract dopaminergic effects of DNSP-11; mechanistic conflict with unknown clinical outcome.

      Estimated Cost

      Generic / Research
      ~$44 per 10 mg vial (~$4.40/mg); at 300 mcg/day ≈ $1.32/day or ~$40/month

      Pricing updated 2026-04-09

      DNSP-11 Side Effects

      No human safety data exists for DNSP-11. Zero. Every piece of tolerability information comes from rats and rhesus macaques. That alone should shape how you think about risk here.

      In rat studies, no observable adverse effects were reported at any tested dose (100, 300, or 1000 mcg intranasally). The dose-escalation study in non-human primates pushed up to 10 mg/day intranasally for 10 weeks, and Stenslik's group found no adverse behavioral effects and no weight loss [3]. Those are encouraging animal signals, but they tell you nothing definitive about human tolerability.

      The most plausible immediate concern with intranasal administration is nasal irritation from the spray device itself. This is mechanical, not pharmacological, and common with any intranasal peptide.

      There's a theoretical immunogenicity question. Full-length GDNF protein triggered anti-GDNF antibody formation in human clinical trials. Whether DNSP-11, a much smaller fragment using a different receptor pathway, carries similar immunogenic risk is completely unstudied. No antibody data has been collected for DNSP-11 in any species.

      Because DNSP-11 increases endogenous dopamine synthesis via ERK1/2 activation, signs of dopaminergic excess are a theoretical risk: agitation, restlessness, insomnia, or dyskinesia. None of these have been observed in animal studies, but animal models are poor at capturing subjective neurological symptoms.

      The interaction risk with dopaminergic medications deserves serious attention. Combining DNSP-11 with levodopa, dopamine agonists like pramipexole or ropinirole, or MAO-B inhibitors like selegiline could produce unpredictable dopaminergic excess. No combination data exists. This is not a compound to stack casually with Parkinson's medications.

      Contraindications: pregnancy and breastfeeding (zero reproductive toxicology data), individuals under 25 (effects on developing nervous systems unstudied), active cancer or CNS tumors (neurotrophic stimulation could theoretically promote tumor growth), and known hypersensitivity to GDNF-derived compounds.

      Stop immediately if you experience headache, dizziness, tremor, unusual mood changes, sleep disruption, or any sign of dopaminergic excess. There is no established protocol for managing DNSP-11 adverse effects because no human adverse events have ever been formally documented.

      Common Issues & Solutions

      Volume precision is critical: at 2 mL BAC water reconstitution of a 10 mg vial, each 10 µL = 50 mcg: a 10 µL pipetting error at the 300 mcg target dose represents a 3.3% deviation. Use precision atomizers; standard insulin syringe markings are too coarse for reliable 60 µL accuracy.

      Intranasal technique matters for CNS delivery: tilt head slightly forward (not backward), deliver with a quick pump, sniff gently after each actuation. Nasal congestion blocks olfactory absorption: postpone dosing when significantly congested.

      Do not confuse the 28-day biological effect (single intranigral injection in rats) with intranasal dosing outcomes. The extended duration is from direct injection into the substantia nigra, not from intranasal delivery. Daily intranasal dosing is still required.

      500 mcg 'aggressive' dose has no animal precedent: Stenslik 2015 tested 100/300/1000 mcg and identified 300 mcg; 500 mcg is an interpolated value with zero supporting data and no evidence it outperforms 300 mcg.

      Verify C-terminal amidation (-NH2) in the CoA before use: DNSP-11 sequence is PPEAPAEDRSL-NH2 (MW 1210.33 Da). Non-amidated product has different biological activity properties.

      Ask AI about this page

      Ask AI for a second opinion on DNSP-11 dosing and side effects

      Contraindications

      • Pregnancy or breastfeeding: no reproductive toxicology data exists for this compound
      • Individuals under 25: effects on developing nervous systems are entirely unstudied
      • Active cancer or history of CNS tumors: neurotrophic stimulation could theoretically promote tumor growth
      • Known hypersensitivity to GDNF-derived compounds
      • Individuals taking dopaminergic medications (levodopa, dopamine agonists): combined effects on dopamine levels are unstudied and could be unpredictable

      Drug Interactions

      • Levodopa/carbidopa: DNSP-11 increases endogenous dopamine levels; combined use could theoretically lead to dopaminergic excess
      • Dopamine agonists (pramipexole, ropinirole): additive dopaminergic effects are unstudied and may carry risk
      • MAO-B inhibitors (selegiline, rasagiline): both increase dopamine availability through different mechanisms; interaction effects unknown
      • Antipsychotics (dopamine antagonists): may counteract the dopaminergic effects of DNSP-11; no interaction data exists
      • Other neurotrophic peptides (Cerebrolysin, Semax, P21): no combination data available; use caution when stacking

      Product Quality

      Recommended Monitoring

      TestWhenTarget
      Neurological self-assessment (informal)Weekly during active dosing cycleNot listed
      Urinary HVA/DOPAC (research context only)Baseline and end of 4-week cycle if accessibleNo established target range for this indication
      Neurological self-assessment (informal)

      No validated clinical monitoring protocol exists for DNSP-11 in humans. Self-monitor for any unusual neurological changes: headache, mood shifts, unusual energy levels, tremor, sleep disturbance.

      Urinary HVA/DOPAC (research context only)

      DNSP-11 increases dopamine turnover; urinary homovanillic acid (HVA) is a dopamine metabolite that could theoretically reflect dopaminergic activity changes. Not a validated monitoring test for DNSP-11 and not routinely available clinically.

      DNSP-11 Before and After

      Weeks 1-2

      No established human timeline exists. In animal models, neurochemical changes (increased dopamine turnover) were measurable within the first week of repeated intranasal dosing. Any perceived effects in humans during this window are speculative.

      Weeks 2-4

      In rat studies, 3 weeks of repeated intranasal dosing at 300 mcg produced measurable increases in dopamine turnover in both the striatum and substantia nigra. Neuroprotective effects in 6-OHDA lesion models were apparent in this timeframe.

      Weeks 4-8

      Extended dosing data comes from non-human primate studies where 10 weeks of repeated intranasal delivery was well tolerated. In rats, a single intranigral injection maintained elevated dopamine levels for up to 28 days, suggesting prolonged duration of activity.

      What to Expect

      Week 1: No one knows what DNSP-11 does in humans during the first week. In rats, neurochemical changes (increased dopamine turnover) showed up within the first week of repeated intranasal dosing at 300 mcg. ERK1/2 phosphorylation activates within hours of exposure in cell culture. Nasal irritation from the spray device is the most likely immediate issue. No pharmacological side effects were documented in animal studies at standard doses.

      Weeks 2 to 4: This is where the animal data gets interesting. Three weeks of repeated intranasal dosing at 300 mcg produced measurable increases in dopamine turnover in both the striatum and substantia nigra in rats, with TH-positive neuron sparing in the 6-OHDA model (Stenslik 2015). No adverse effects at the 100 to 300 mcg dose range. No human reports exist for comparison.

      NHP reference at 10 weeks continuous: The longest tolerability data comes from rhesus macaques. Stenslik's group ran escalating intranasal doses up to 10 mg/day for 10 weeks with no adverse behavioral effects or weight loss [3]. NHP tolerability does not confirm human tolerability.

      28-day single injection reference: A single direct injection into the rat substantia nigra kept dopamine and DOPAC levels raised for 28 days. This is a surgical route in animals, not intranasal human dosing. The community frequently misquotes this data point to suggest once-monthly intranasal dosing is enough. It is not.

      Detailed Timeline: Science vs Community

      Week 1
      Science

      In rats, neurochemical changes (increased dopamine turnover) were measurable within the first week of repeated intranasal dosing at 300 mcg. ERK1/2 phosphorylation in dopaminergic neurons activates within hours of exposure in vitro.

      Community

      No human data available. No user-reported first-week experiences exist.

      Weeks 2–4
      Science

      3 weeks of repeated intranasal dosing at 300 mcg produced measurable increases in dopamine turnover in striatum and substantia nigra in rats, with TH+ neuron sparing in the 6-OHDA model (Stenslik 2015).

      Community

      No human reports available for comparison.

      NHP reference: 10 weeks continuous
      Science

      Rhesus macaques tolerated escalating intranasal doses up to 10 mg/day for 10 weeks with no adverse behavioral effects or weight loss (Stenslik 2018, PMID 29614295).

      Community

      No human data. NHP tolerability does not confirm human tolerability.

      Rat intranigral injection (reference data point only)
      Science

      A single stereotaxic injection into rat substantia nigra elevated dopamine/DOPAC levels for up to 28 days. This is a direct surgical injection route in animals: NOT applicable to intranasal human dosing protocols.

      Community

      This data point is frequently misquoted to suggest once-monthly intranasal dosing is sufficient. It is not: the 28-day duration was from direct intranigral injection, not intranasal delivery.

      Pharmacokinetics

      Half-Life
      N/A
      Bioavailability
      Intranasal: demonstrated CNS penetration in rats (125I-DNSP-11 detected in striatum and substantia nigra within 30 min). SC: not formally characterized. No human bioavailability data.
      Tmax
      Brain Tmax ~30 minutes after intranasal administration in rats (tracer study)
      Data Confidence
      low

      Source: No formal pharmacokinetic half-life data published for DNSP-11. A single intranigral injection maintained elevated dopamine and DOPAC levels for up to 28 days in rats, suggesting prolonged biological activity far exceeding the expected plasma half-life of an 11-amino-acid peptide. Intranasal tracer studies showed brain distribution within 30 minutes.

      Molecular Profile

      Amino Acids
      11
      Sequence
      PPEAPAEDRSL
      HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
      Identifiers
      CAS: Not assigned (research peptide, no CAS registry entry found)

      Who Should Consider DNSP-11

      • Researchers investigating GDNF-pathway neurotrophic factors for dopaminergic neuroprotection
      • Scientists studying preclinical approaches to Parkinson's disease
      • Individuals exploring experimental neuroprotective peptides under medical supervision
      • Those researching intranasal delivery of neurotrophic factors to the central nervous system

      Related Peptides

      What Changed for DNSP-11

      No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

      Peptide Schedule Research TeamReviewed Apr 7, 20265 Citations

      References

      1. [1]Dopamine neuron stimulating actions of a GDNF propeptide (Bradley et al., 2010) (opens in a new tab)PubMed (opens in a new tab)PubMed
      2. [2]Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease (Stenslik et al., 2015) (opens in a new tab)PubMed (opens in a new tab)PubMed
      3. [3]Methodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques (Stenslik et al., 2018) (opens in a new tab)PubMed (opens in a new tab)PubMed
      4. [4]Dynamic changes in dopamine neuron function after DNSP-11 treatment: effects in vivo and increased ERK 1/2 phosphorylation in vitro (Peptides 2014) (opens in a new tab)PubMed (opens in a new tab)PubMed
      5. [5]Evaluation of the physical and in vitro protective activity of three synthetic peptides derived from the pro- and mature GDNF sequence (Kelps et al., 2011) (opens in a new tab)PubMed (opens in a new tab)PubMed

      Related Tools

      Storage & Stability

      Before Reconstitution
      Room temperature up to 1 month, refrigerate or freeze for long-term storage
      After Reconstitution
      Refrigerate at 2-8°C, use within 4 weeks
      Temperature
      2-8°C (36-46°F) recommended

      Frequently Asked Questions

      No human trials have been conducted. Safety data comes entirely from rats and rhesus macaques. NHP studies found no observable adverse effects from escalating doses up to 10 mg/day intranasally over 10 weeks, but this does not establish human safety. Any human use is self-experimentation with unknown risk.

      Effects lasting up to 28 days in rats after a single intranigral injection are thought to result from sustained intracellular ERK1/2 signaling cascades rather than continuous plasma drug levels. The peptide triggers a cellular program that outlasts the molecule itself.

      Intranasal is the best-studied route. Tracer studies confirmed brain distribution (striatum and substantia nigra) within 30 minutes of intranasal administration in rats. SC data is essentially absent. Intranasal is the appropriate first approach.

      GDNF requires the GFRα1/RET receptor complex and has poor CNS penetration after peripheral administration. DNSP-11 acts through a distinct ERK1/2 pathway, bypasses the GFRα1 receptor, and penetrates the CNS via intranasal delivery. No anti-GDNF antibody formation has been observed with DNSP-11; a known problem with GDNF gene therapy.

      Primarily Bradley and colleagues at the University of Kentucky. No pharmaceutical company has announced clinical development. The research is academic-only as of 2026.